Immunoproteasome components LMP2, PSME1, and PSME2 as novel tissue biomarkers predicting response and survival in neoadjuvant chemoimmunotherapy for resectable NSCLC

BackgroundWhile neoadjuvant chemoimmunotherapy (NACI) improves outcomes in resectable non-small cell lung cancer (NSCLC), a significant subset of patients exhibits innate resistance. Biomarkers predicting response are urgently needed. Given the central role of antigen processing in immunotherapy eff...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ru Xie, Ke Zhai, Jinming Yu, Miaoqing Zhao
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-09-01
Col·lecció:	Frontiers in Immunology
Matèries:	neoadjuvant immunotherapy combined with chemotherapy predictive markers NSCLC LMP2 PSME1 PSME2
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1654573/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!